DE19517889A1 - Prepn. of N-acetyl-2-amino-2-desoxy-beta-D-glucopyranosides - Google Patents
Prepn. of N-acetyl-2-amino-2-desoxy-beta-D-glucopyranosidesInfo
- Publication number
- DE19517889A1 DE19517889A1 DE19517889A DE19517889A DE19517889A1 DE 19517889 A1 DE19517889 A1 DE 19517889A1 DE 19517889 A DE19517889 A DE 19517889A DE 19517889 A DE19517889 A DE 19517889A DE 19517889 A1 DE19517889 A1 DE 19517889A1
- Authority
- DE
- Germany
- Prior art keywords
- acetyl
- chloride
- amino
- deoxy
- glucopyranosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Saccharide Compounds (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Die Erfindung betrifft ein Verfahren zur gezielten Synthese von β-glycosidisch verknüpften N-Acetyglucosaminderivaten und im besonderen von N-Acetyl-2- amino-2-desoxy-β-D-glucopyranosiden.The invention relates to a method for the targeted synthesis of β-glycosidic linked N-acetyglucosamine derivatives and in particular N-acetyl-2- amino-2-deoxy-β-D-glucopyranosides.
Die Bedeutung der Kohlenhydrate im Rahmen physiologisch relevanter Erkennungsprozesse ist erst in den letzten Jahren näher untersucht und entschlüsselt worden (T. Feizi, Biochem. J. 1987, (245), 1; S. Hakamori, Adv. Cancer Res. 1989, (52), 257; M.P. Bevilacqua et. al., Science 1989, (243), 1160).The importance of carbohydrates in the context of physiologically relevant Recognition processes have only been examined in more detail in recent years have been decrypted (T. Feizi, Biochem. J. 1987, (245), 1; S. Hakamori, Adv. Cancer Res. 1989, (52), 257; M.P. Bevilacqua et. al., Science 1989, (243), 1160).
Man erkannte, daß die Kohlenhydrate, neben den Proteinen und Nucleinsäuren, der dritte wichtige Informationsträger des Lebens sind, da sie in der Regel eine große Anzahl von Stereozentren besitzen und so eine Vielzahl von Informationen beinhalten können. Ihre Anordnung auf der Zelloberfläche in Form von Liganden ermöglicht Ihnen, aufgrund von Rezeptor-Ligandenbindungen eine entscheidende Rolle bei der interzellulären Kommunikation und damit auch bei interzellulären Erkennungsprozessen zu spielen. Infolge dieser besonderen Bedeutung der Kohlenhydrate bei physiologisch relevanten Erkennungsprozessen kommt ihrer Synthese ein gesteigertes Interesse zu.It was recognized that the carbohydrates, in addition to the proteins and nucleic acids, The third important information carrier of life, as they are usually one have a large number of stereo centers and so a lot of information can include. Their arrangement on the cell surface in the form of ligands enables you to make a crucial one based on receptor ligand binding Role in intercellular communication and thus also in intercellular To play recognition processes. As a result of this particular importance of Carbohydrates in physiologically relevant recognition processes come theirs Synthesis increased interest too.
Ein wichtiger Baustein in der Oligosaccaridsynthese stellt das N-Acetyglucosamin (N-Acetyl-2-amino-2-desoxy-D-glucopyranose) 1 dar, das in in vielen physiologisch relevanten Oligosaccharidstrukturen vorkommt (z. B. J.C. Paulson et al., Science 1990, (250), 1130). This is an important building block in oligosaccharide synthesis N-acetyglucosamine (N-acetyl-2-amino-2-deoxy-D-glucopyranose) 1, which in occurs in many physiologically relevant oligosaccharide structures (e.g. J.C. Paulson et al., Science 1990, (250), 1130).
Bei der Synthese von Oligosacchariden werden Monosaccharidbausteine zusammengefügt, die in der Regel 4 bis 5 Hydroxylgruppen enthalten, welche sich in bezug auf deren Reaktivität nur wenig unterscheiden. Die gezielte Synthese der Oligosaccharide erfordert daher eine komplexe, aufeinander abgestimmte Schutzgruppenstrategie, die eine selektive Einführung und Abspaltung der verschiedenen Schutzgruppen ermöglicht. Bei der Glycosidsynthese ist es wichtig; die C-1-Position des Glycosyldonors zu aktivieren und dabei gleichzeitig die übrigen Hydroxylgruppen zu schützen, so daß diese nicht an der Kupplungsreaktion teilnehmen. Glycosyldonor und Glycosylakzeptor werden in der Regel in Gegenwart eines aktivierenden Katalysators miteinander verknüpft. Hierbei stellt die Kontrolle der Selektivität der glycosidischen Verknüpfung (d. h. α- oder β-Konfiguration des an der erzeugten glycosidischen Bindung beteiligten anomeren Kohlenstoffatoms) ein weiteres Problem dar. Zur Lösung dieses Problems sind die verschiedensten Verfahren entwickelt worden (Übersichten s. z. B. R. R. Schmidt, Pure & Appl. Chem. 1989, (61), 1257).In the synthesis of oligosaccharides, monosaccharide building blocks are used put together, which usually contain 4 to 5 hydroxyl groups, which differ little in their reactivity. The targeted Synthesis of the oligosaccharides therefore requires a complex, one on the other coordinated protection group strategy, which is a selective introduction and The different protective groups can be split off. In the Glycoside synthesis is important; the C-1 position of the glycosyl donor activate while protecting the other hydroxyl groups, so that they do not participate in the coupling reaction. Glycosyl donor and Glycosyl acceptors are usually activated in the presence of an Catalyst linked together. This is the control of selectivity the glycosidic linkage (i.e., α or β configuration of the at the generated glycosidic bond involved anomeric carbon atom) is another problem. To solve this problem are the most varied Processes have been developed (for overviews, see e.g. R. R. Schmidt, Pure & Appl. Chem. 1989, (61), 1257).
Viele Verfahren haben jedoch den Nachteil, daß sie unter Verwendung von teuren oder sehr giftigen Schwermetallen als Katalysatoren geringe Ausbeuten oder schlechte Selektivitäten ergeben.However, many methods have the disadvantage of using expensive or very toxic heavy metals as catalysts low yields or result in poor selectivities.
Zur Darstellung von N-Acetylglucosaminderivaten sind eine Reihe verschiedenster N-Acetylglucosamindonoren eingesetzt worden (z. B. T. Mukaiyama et al., Chem. Lett. 1984, 907; K. Higashi, Chem. Pharm. Bull. 1990, (38), 3280).There are a number of ways to prepare N-acetylglucosamine derivatives various N-acetylglucosamine donors have been used (e.g. T. Mukaiyama et al., Chem. Lett. 1984, 907; K. Higashi, Chem. Pharm. Bull. 1990, (38), 3280).
Für eine effiziente Synthese in größerem Maßstab ist die gute Zugänglichkeit der Startmaterialien von besonderer Bedeutung. Von den verschiedenen N-Acetylglucosamindonoren ist das peracetylierte Chlorid der N-Acetyl-2-amino- 2-desoxy-D-glucopyranose, das N-Acetyl-2-amino-2-desoxy-3,4,6-tri-O-acetyl-α- D-glucopyranosylchlorid 2, aus N-Acetyl-Glucosamin durch Umsetzung mit Acetylchlorid direkt in einer Stufe zugänglich (D. Horton, Org. Synth., Coll. Vol. V, 1973, 1).For an efficient synthesis on a larger scale, the good accessibility is the Starting materials of particular importance. Of the different N-acetylglucosamine donors are the peracetylated chloride of N-acetyl-2-amino 2-deoxy-D-glucopyranose, the N-acetyl-2-amino-2-deoxy-3,4,6-tri-O-acetyl-α- D-glucopyranosyl chloride 2, from N-acetyl-glucosamine by reaction with Acetyl chloride directly accessible in one step (D. Horton, Org. Synth., Coll. Vol. V, 1973, 1).
Als geeigneter Katalysator hat sich Zinkchlorid bewährt, mittels welchem bei der Umsetzung von N-Acetyl-2-amino-2-desoxy-3,4,6-tri-O-acetyl-α-D- glucopyranosylchlorid (2) mit Lactosederivaten a/ß Verhältnisse bezüglich der Konfiguration der Produkte von bis zu 1/5 erreicht werden können (T. Norberg, J. Carbohydr. Chem. 1990, (9), 721).Zinc chloride has proven to be a suitable catalyst, by means of which the Reaction of N-acetyl-2-amino-2-deoxy-3,4,6-tri-O-acetyl-α-D- glucopyranosyl chloride (2) with lactose derivatives a / ß ratios with respect to Configuration of the products of up to 1/5 can be achieved (T. Norberg, J. Carbohydr. Chem. 1990, (9), 721).
In einem kürzlich beschriebenen Verfahren wurde der Glycosyldonor 2 mit verschiedenen Glycosylakzeptoren unter Zinkchlorid-Katalyse in Gegenwart von verschiedenen Cokatalysatoren umgesetzt (R. Bittman, Tetrahedron Lett., 1994, (35), 505). Als Cokatalysator wurde beispielsweise Tritylchlorid (Triphenylmethylchlorid) eingesetzt. Bei Verwendung dieser Katalysatorkombination waren jedoch längere Reaktionszeiten notwendig, und es traten Anomerisierungseffekte auf Kosten der ß-Selektivität auf. Darüber hinaus reagierte eine Vielzahl verschiedener Glycosylakzeptoren unter diesen Bedingungen nicht mit dem Glycosyldonor 2.In a recently described process, the glycosyl donor 2 was used different glycosyl acceptors under zinc chloride catalysis in the presence of various cocatalysts (R. Bittman, Tetrahedron Lett., 1994, (35), 505). Trityl chloride, for example, was used as the cocatalyst (Triphenylmethyl chloride) used. When using this However, longer reaction times were necessary, and anomerization effects occurred at the expense of the β selectivity. About that a large number of different glycosyl acceptors reacted among them Conditions not with the glycosyl donor 2.
Aufgabe der Erfindung ist es, ein Verfahren zur Synthese von β-glycosidisch verknüpften N-Acetylglucosaminderivaten, im besonderen von N-Acetyl-2- amino-2-desoxy-β-D-glucopyranosiden, bereitzustellen, welches bessere Ausbeuten sowie eine höhere β-Selektivität ergibt, keine Anomerisierung der erzeugten glycosidischen Bindung zur Folge hat und auf eine große Zahl von Glycosylakzeptoren, insbesondere Alkoholen, anwendbar ist.The object of the invention is to provide a process for the synthesis of β-glycosidic linked N-acetylglucosamine derivatives, especially N-acetyl-2- amino-2-deoxy-β-D-glucopyranosiden, which is better Yields and a higher β selectivity results in no anomerization of the generated glycosidic bond and to a large number of Glycosyl acceptors, especially alcohols, is applicable.
Die Aufgabe wird erfindungsgemäß gelöst durch ein Verfahren zur Herstellung von N-Acetyl-2-amino-2-desoxy-β-D-glucopyranosiden durch Umsetzung von N- Acetyl-2-amino-2-desoxy-3,4,6-tri-O-acetyl-α-D-glucopyranosylchlorid (Donor 2) mit einem Glycosylakzeptor in Gegenwart von Zinkchlorid und eines Cokatalysators in einem Lösungsmittel, welches Verfahren sich dadurch auszeichnet, daß als Cokatalysator ein 4,4′-Dimethoxytriphenylmethylhalogenid eingesetzt wird.The object is achieved according to the invention by a method for the production of N-acetyl-2-amino-2-deoxy-β-D-glucopyranosides by reacting N- Acetyl-2-amino-2-deoxy-3,4,6-tri-O-acetyl-α-D-glucopyranosyl chloride (donor 2) with a glycosyl acceptor in the presence of zinc chloride and one Cocatalyst in a solvent, which process is characterized distinguishes that as a cocatalyst a 4,4'-dimethoxytriphenylmethyl halide is used.
Vorzugsweise werden bei dem erfindungsgemäßen Verfahren das Zinkchlorid und das 4,4′-Dimethoxytriphenylmethylhalogenid in einem molaren Verhältnis zueinander von 1 : 1 eingesetzt.Zinc chloride is preferred in the process according to the invention and the 4,4'-dimethoxytriphenylmethyl halide in a molar ratio used 1: 1 to each other.
Als Lösungsmittel eignet sich insbesondere Dichlormethan.Dichloromethane is particularly suitable as the solvent.
Bei dem erfindungsgemäßen Verfahren wird vorzugsweise das wohlfeile 4,4′- Dimethoxytriphenylmethylchlorid als Cokatalysator eingesetzt.In the method according to the invention, the cheap 4,4'- Dimethoxytriphenylmethylchloride used as a cocatalyst.
Bei der Variation des Halogenids (Cl, Br, I) der Dimethoxytrityhalogenide (Darstellung siehe: Roedig, A. in Houben Weyl, Bd. V/4, 1960, 595 ff.) kann jedoch kein Unterschied in bezug auf Reaktivität und β-Selektivität beobachtet werden.In the variation of the halide (Cl, Br, I) of the dimethoxytrity halides (For illustration see: Roedig, A. in Houben Weyl, Vol. V / 4, 1960, 595 ff.) however, no difference in reactivity and β selectivity was observed will.
Der Einsatz der erfindungsgemäßen Katalysatorkombination führt zu einer deutlichen Verkürzung der Reaktionszeit im Vergleich zu dem bekannten Verfahren auch bei Einsatz im großen Maßstab. The use of the catalyst combination according to the invention leads to a significant reduction in response time compared to the known Process even when used on a large scale.
Durch die veränderten Bedingungen kann ferner der Überschuß des Donors 2 gesenkt werden, und sehr unterschiedliche Alkohole können nahezu ohne Einschränkung als Kupplungspartner umgesetzt werden. Die chromatographische Reinigung der Produkte ist durch die veränderten Bedingungen ebenfalls deutlich verbessert. Infolge der kürzeren Reaktionszeit werden Anomerisierungseffekte weitestgehend vermieden, welches die gezielte Synthese von β-glycosidisch verknüpften N-Acetylglucosaminderivaten in guten Ausbeuten ermöglicht.Due to the changed conditions, the excess of donor 2 can be lowered, and very different alcohols can be used almost without Restriction can be implemented as a coupling partner. The chromatographic Cleaning of the products is also clear due to the changed conditions improved. Due to the shorter reaction time there are anomerization effects largely avoided, which the targeted synthesis of β-glycosidic linked N-acetylglucosamine derivatives in good yields.
In den nachfolgenden Beispielen werden die Umsetzungen des N-Acetyl-2- amino-2-desoxy-3,4,6-tri-O-acetyl-α-D-glucopyranosylchlorids 2 mit jeweils unterschiedlichen Glycosylakzeptoren gemäß nachfolgendem Reaktionsschema beschrieben. Die dabei erhaltenen Verbindungen 3a-d sind wertvolle Zwischenstufen beim Aufbau komplexer Oligosaccharide (z. B. W.Stahl et al., Angew. Chem Int. Ed. Engl., 1994, (33), 2096). In the examples below, the reactions of N-acetyl-2- amino-2-deoxy-3,4,6-tri-O-acetyl-α-D-glucopyranosyl chloride 2 with each different glycosyl acceptors according to the following reaction scheme described. The compounds 3a-d obtained are valuable Intermediate stages in the formation of complex oligosaccharides (e.g. W.Stahl et al., Appl. Chem Int. Ed. Engl., 1994, (33), 2096).
Die ¹H-NMR Spektren wurden mit dem Gerät WT 300 der Fa. Bruker bei 300 MHZ aufgenommen. Zur Dünnschichtchromatographie wurden DC-Fertigplatten der Fa. Merck mit Kieselgel 60 F254 eingesetzt. Zur Säulenchromatograpie wurde Kieselgel 60 (Korngröße 0.040-0.063 mm, 230-400 mesh) der Fa. Merck verwandt.The 1 H-NMR spectra were obtained using the WT 300 from Bruker at 300 MHZ added. Ready-to-use TLC plates were used for thin layer chromatography from Merck with silica gel 60 F254. For column chromatography silica gel 60 (grain size 0.040-0.063 mm, 230-400 mesh) from Fa. Merck related.
Zu einer Suspension von Zink(II)-chlorid (1 eq., 80 g, 0,595 mol) und 4,4′-
Dimethoxytritylchlorid (1 eq., 205 g, 0,595 mol) in trockenem Dichlormethan
(3 l) werden das Chlorid 2 (1.3 eq, 282 g, 0,773 mol) und Z-6 Aminohexanol (1
eq. 150 g, 0,595 mol) gegeben. Das Gemisch wird 3 h bei Raumtemperatur
gerührt (DC Kontrolle: Methylenchlorid/Methanol 20/1). Nach Zugabe von
Methylenchlorid (1 l) wird mit ges. Natriumhydrogencarbonatlösung gewaschen.
Nach Entfernen des Lösungsmittels am Rotationsverdampfer wird der Rückstand
säulenchromatographisch (Methylenchlorid/Methanol 100/1-20/1) gereinigt. Man
erhält das Glycosid 3a in 93% Ausbeute (321 g).
Rf-Wert:
0.35 ( Methylenchlorid/Methanol 20 /1)
¹H-NMR (300 MHZ, CDCl₃):
7,38-7,28 (m, 5H); 6,00 (d, 1H); 5,29 (dd, 1H); 5,12 (dd, 1H); 5.05 (dd, 1H);
4.90 (t, 1H); 4.63 (d, J = 8,0 Hz, 1H); 4.25 (dd, 1H); 4,11 (dd, 1H);
3,90-3,72 (m, 2H); 3,67-3,58 (m, 1H); 3,52-3,43 (m, 1H); 3,26-3,08 (m, 2H);
2,12-1,94 (4 s, 12 H); 160-1,43 (m, 4 H); 1,39-1,28 (m, 4 H) ppm.The chloride 2 becomes a suspension of zinc (II) chloride (1 eq., 80 g, 0.595 mol) and 4,4′-dimethoxytrityl chloride (1 eq., 205 g, 0.595 mol) in dry dichloromethane (3 l) (1.3 eq, 282 g, 0.773 mol) and Z-6 aminohexanol (1 eq. 150 g, 0.595 mol) were added. The mixture is stirred for 3 h at room temperature (TLC control: methylene chloride / methanol 20/1). After adding methylene chloride (1 l), the mixture is saturated with sat. Washed sodium bicarbonate solution. After removing the solvent on a rotary evaporator, the residue is purified by column chromatography (methylene chloride / methanol 100 / 1-20 / 1). The glycoside 3a is obtained in 93% yield (321 g).
R f value: 0.35 (methylene chloride / methanol 20/1)
1 H-NMR (300 MHz, CDCl₃): 7.38-7.28 (m, 5H); 6.00 (d, 1H); 5.29 (dd, 1H); 5.12 (dd, 1H); 5.05 (dd, 1H); 4.90 (t, 1H); 4.63 (d, J = 8.0 Hz, 1H); 4.25 (dd, 1H); 4.11 (dd, 1H); 3.90-3.72 (m, 2H); 3.67-3.58 (m, 1H); 3.52-3.43 (m, 1H); 3.26-3.08 (m, 2H); 2.12-1.94 (4s, 12H); 160-1.43 (m, 4H); 1.39-1.28 (m, 4H) ppm.
Zu einer Suspension von Zink(II)-chlorid (1 eq., 1,39 g) und 4,4′-
Dimethoxytritylchlorid (1 eq., 1,22 g) in trockenem Dichlormethan (40 ml)
werden das Chlorid 2 (1.3 eq, 4,97 g) und N-Hydroxyethylphthalimid (1 eq.,
2,00 g) gegeben. Das Gemisch wird 1 h bei Raumtemperatur gerührt (DC
Kontrolle: Methylenchlorid/Methanol 20/1). Nach Zugabe von Methylenchlorid
wird mit ges. Natriumhydrogencarbonatlösung gewaschen. Nach Entfernen des
Lösungsmittels am Rotationsverdampfer wird der Rückstand
säulenchromatographisch (Methylenchlorid/Methanol 100/1-40/1) gereinigt. Man
erhält das Glycosid 3b in 91% Ausbeute (4,94 g).
Rf-Wert: 0.35 ( Methylenchlorid/Methanol 20 /1)
¹H-NMR (300 MHZ, CDCl₃):
7,9 (m, 2 H); 7,7 (m, 2H); 5,95 (d, 1H); 5,30-5,05 (m, 2H); 4,95 (d, J = 8,0
Hz, 1H); 4,20-3,890 (m, 7H); 3,60 (dd, 1H), 2,10-2,00 (4 s, 12 H) pprn.To a suspension of zinc (II) chloride (1 eq., 1.39 g) and 4,4'-dimethoxytrityl chloride (1 eq., 1.22 g) in dry dichloromethane (40 ml), the chloride 2 (1.3 eq, 4.97 g) and N-hydroxyethylphthalimide (1 eq., 2.00 g). The mixture is stirred at room temperature for 1 h (TLC control: methylene chloride / methanol 20/1). After adding methylene chloride, it is saturated with. Washed sodium bicarbonate solution. After removing the solvent on a rotary evaporator, the residue is purified by column chromatography (methylene chloride / methanol 100 / 1-40 / 1). The glycoside 3b is obtained in 91% yield (4.94 g).
R f value: 0.35 (methylene chloride / methanol 20/1)
1 H-NMR (300 MHz, CDCl₃): 7.9 (m, 2 H); 7.7 (m. 2H); 5.95 (d. 1H); 5.30-5.05 (m, 2H); 4.95 (d, J = 8.0 Hz, 1H); 4.20-3.890 (m, 7H); 3.60 (dd, 1H), 2.10-2.00 (4 s, 12 H) pprn.
Zu einer Suspension von Zink(II)-chlorid (1 eq., 1,55 g) und 4,4′-
Dimethoxytritylchlorid (1 eq., 3,84 g) in trockenem Dichlormethan (40 ml)
werden das Chlorid 2 (1.3 eq, 5,38 g) und n-Pentanol (1 eq., 2,00 g) gegeben.
Das Gemisch wird 1 h bei Raumtemperatur gerührt (DC Kontrolle:
Methylenchlorid/Methanol 20/1). Nach Zugabe von Methylenchlorid wird mit
ges. Natriumhydrogencarbonatlösung gewaschen. Nach Entfernen des
Lösungsmittels am Rotationsverdampfer wird der Rückstand
säulenchromatographisch (Methylenchlorid/ Methanol 100/1-40/1) gereinigt.
Man erhält das Glycosid 3c in 85% Ausbeute (4,01 g).
Rf-Wert: 0.35 ( Methylenchlorid/Methanol 20 /1)
¹H-NMR (300 MHZ, CDCI₃):
7,38-7,28 (m, 5H); 6,00 (d, 1H); 5,30 (dd, 1H); 5,15 (dd, 1H); 5.05 (dd, 1H);
4.95 (t, 1H); 4.65 (d, J = 8,5 Hz, 1H); 4.20 (dd, 1H); 4,10 (dd, 1H);
3,90-3,70 (m, 2H); 3,67-3,58 (m, 1H); 3,52-,43 (m, 1H); 2,12-,94 (4 s, 12
H); 165-1,30 (m, 8 H) ppm.To a suspension of zinc (II) chloride (1 eq., 1.55 g) and 4,4'-dimethoxytrityl chloride (1 eq., 3.84 g) in dry dichloromethane (40 ml), the chloride 2 (1.3 eq, 5.38 g) and n-pentanol (1 eq., 2.00 g). The mixture is stirred at room temperature for 1 h (TLC control: methylene chloride / methanol 20/1). After adding methylene chloride, it is saturated with. Washed sodium bicarbonate solution. After removing the solvent on a rotary evaporator, the residue is purified by column chromatography (methylene chloride / methanol 100 / 1-40 / 1). The glycoside 3c is obtained in 85% yield (4.01 g).
R f value: 0.35 (methylene chloride / methanol 20/1)
1 H-NMR (300 MHz, CDCI₃): 7.38-7.28 (m, 5H); 6.00 (d, 1H); 5.30 (dd, 1H); 5.15 (dd, 1H); 5.05 (dd, 1H); 4.95 (t, 1H); 4.65 (d, J = 8.5 Hz, 1H); 4.20 (dd, 1H); 4.10 (dd, 1H); 3.90-3.70 (m, 2H); 3.67-3.58 (m, 1H); 3.52-, 43 (m, 1H); 2.12-.94 (4 s, 12H); 165-1.30 (m, 8H) ppm.
Zu einer Suspension von Zink(II)-chlorid (1 eq., 0.49 g) und 4,4′-
Dimethoxytritylchlorid (1 eq., 1,23 g) in trockenem Dichlormethan (40 ml)
werden das Chlorid 2 (1.3 eq, 1 ,72 g) und N-Benzyloxycarbonyl-6-aminohexyl-
N-acetyl-2-amino-2-desoxy-4,6-O-benzyliden-β-D-glucopyranosid (1 eq., 2,00 g)
gegeben. Das Gemisch wird 1 h bei Raumtemperatur gerührt (DC Kontrolle:
Methylenchlorid/Methanol 20/1). Nach Zugabe von Methylenchlorid wird mit
ges. Natriumhydrogencarbonatlösung gewaschen. Nach Entfernen des
Lösungsmittels am Rotationsverdampfer wird der Rückstand
säulenchromatographisch (Methylenchlorid/ Methanol 100/1-40/1) gereinigt.
Man erhält das Glycosid 3d in 86% Ausbeute (2,74 g).
Rf-Wert: 0.35 ( Methylenchlorid/Methanol 20 /1)
¹H-NMR (300 MHZ, CDCl₃):
7,50-7,25 (m, 10H); 5,80 (m, 1H); 5,55 (s, 1H); 5,18 (m, 1H); 5,05 (s, 2H);
4,75 (d, 1H); 4,69 (d, J = 8,0 Hz, 1H); 4,60 (d, J = 8.0 Hz, 1H); 4.32-4.00
(m, 5H); 3,80 (m, 3H); 3,50 (m, 1H); 3,17 (m, 2H); 2,15-1,90 (5 s, 15H);
1,60-1,35 (m, 8H) ppm.To a suspension of zinc (II) chloride (1 eq., 0.49 g) and 4,4′-dimethoxytrityl chloride (1 eq., 1.23 g) in dry dichloromethane (40 ml), the chloride 2 (1.3 eq, 1.72 g) and N-benzyloxycarbonyl-6-aminohexyl-N-acetyl-2-amino-2-deoxy-4,6-O-benzylidene-β-D-glucopyranoside (1 eq., 2.00 g) . The mixture is stirred at room temperature for 1 h (TLC control: methylene chloride / methanol 20/1). After adding methylene chloride, it is saturated with. Washed sodium bicarbonate solution. After removing the solvent on a rotary evaporator, the residue is purified by column chromatography (methylene chloride / methanol 100 / 1-40 / 1). The glycoside 3d is obtained in 86% yield (2.74 g).
R f value: 0.35 (methylene chloride / methanol 20/1)
1 H-NMR (300 MHz, CDCl₃): 7.50-7.25 (m, 10H); 5.80 (m, 1H); 5.55 (s, 1H); 5.18 (m, 1H); 5.05 (s. 2H); 4.75 (d. 1H); 4.69 (d, J = 8.0 Hz, 1H); 4.60 (d, J = 8.0 Hz, 1H); 4.32-4.00 (m, 5H); 3.80 (m, 3H); 3.50 (m, 1H); 3.17 (m. 2H); 2.15-1.90 (5 s, 15H); 1.60-1.35 (m, 8H) ppm.
Claims (4)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19517889A DE19517889C2 (en) | 1995-05-16 | 1995-05-16 | Process for the targeted synthesis of β-glycosidically linked N-acetylglucosamine derivatives |
| EP96107500A EP0755939B1 (en) | 1995-05-16 | 1996-05-10 | Method for the targetted synthesis of beta-glycoside bound N-acetyl glucosamine derivatives |
| DE59609865T DE59609865D1 (en) | 1995-05-16 | 1996-05-10 | Process for the targeted synthesis of beta-glycosidically linked N-acetylglucosamine derivatives |
| AT96107500T ATE227731T1 (en) | 1995-05-16 | 1996-05-10 | METHOD FOR THE TARGETED SYNTHESIS OF BETA-GLYCOSIDIC LINKED N-ACETYL GLUCOSAMINE DERIVATIVES |
| JP8119828A JPH08333381A (en) | 1995-05-16 | 1996-05-15 | Specific synthesizing method for beta-glycoside-bonded n-acetylglucosamine derivative |
| CA002176686A CA2176686A1 (en) | 1995-05-16 | 1996-05-15 | Process for the specific synthesis of .beta.-glycosidically linked n-acetylglucosamine derivatives |
| US08/648,717 US5696246A (en) | 1995-05-16 | 1996-05-16 | Process for the specific synthesis of β-glycosidically linked N-acetylpyranoside derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19517889A DE19517889C2 (en) | 1995-05-16 | 1995-05-16 | Process for the targeted synthesis of β-glycosidically linked N-acetylglucosamine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE19517889A1 true DE19517889A1 (en) | 1996-11-21 |
| DE19517889C2 DE19517889C2 (en) | 1998-12-03 |
Family
ID=7762015
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19517889A Expired - Fee Related DE19517889C2 (en) | 1995-05-16 | 1995-05-16 | Process for the targeted synthesis of β-glycosidically linked N-acetylglucosamine derivatives |
| DE59609865T Expired - Fee Related DE59609865D1 (en) | 1995-05-16 | 1996-05-10 | Process for the targeted synthesis of beta-glycosidically linked N-acetylglucosamine derivatives |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE59609865T Expired - Fee Related DE59609865D1 (en) | 1995-05-16 | 1996-05-10 | Process for the targeted synthesis of beta-glycosidically linked N-acetylglucosamine derivatives |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US5696246A (en) |
| EP (1) | EP0755939B1 (en) |
| JP (1) | JPH08333381A (en) |
| AT (1) | ATE227731T1 (en) |
| CA (1) | CA2176686A1 (en) |
| DE (2) | DE19517889C2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19617019A1 (en) * | 1996-04-27 | 1997-11-06 | Beiersdorf Ag | Alkyl-2-acetamino-2-deoxy-glucopyranoside-uronic acids and derivatives, their preparation and their use as surfactants in cosmetic and pharmaceutical preparations |
| PT1001961E (en) * | 1997-08-08 | 2005-04-29 | Aventis Pharma Gmbh | SUBSTITUTED TETRAHYDROPYRANE DERIVATIVES AS A PROCESS FOR THEIR PREPARATION |
| EP1247819A1 (en) * | 2001-04-04 | 2002-10-09 | Dainichiseika Color & Chemicals Mfg. Co. Ltd. | Purified chitins and production process thereof |
| KR100714936B1 (en) * | 2002-10-09 | 2007-05-10 | 카오 가부시키가이샤 | ?-acetylglucosamine Derivatives and Use Thereof |
| CN100358911C (en) * | 2002-10-09 | 2008-01-02 | 花王株式会社 | N-acetylglucosamine derivatives and use thereof |
| CN102241710A (en) * | 2011-04-21 | 2011-11-16 | 南通大学 | Salidroside analogues as well as preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994019360A1 (en) * | 1993-02-23 | 1994-09-01 | The Trustees Of Princeton University | Solution and solid-phase formation of glycosidic linkages |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5243035A (en) * | 1990-02-27 | 1993-09-07 | Drug Delivery System Institute, Ltd. | Sialic acid-containing glycolipid derivatives |
-
1995
- 1995-05-16 DE DE19517889A patent/DE19517889C2/en not_active Expired - Fee Related
-
1996
- 1996-05-10 AT AT96107500T patent/ATE227731T1/en not_active IP Right Cessation
- 1996-05-10 DE DE59609865T patent/DE59609865D1/en not_active Expired - Fee Related
- 1996-05-10 EP EP96107500A patent/EP0755939B1/en not_active Expired - Lifetime
- 1996-05-15 JP JP8119828A patent/JPH08333381A/en active Pending
- 1996-05-15 CA CA002176686A patent/CA2176686A1/en not_active Abandoned
- 1996-05-16 US US08/648,717 patent/US5696246A/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994019360A1 (en) * | 1993-02-23 | 1994-09-01 | The Trustees Of Princeton University | Solution and solid-phase formation of glycosidic linkages |
Non-Patent Citations (7)
| Title |
|---|
| Chem. Pharm. Bull, 1990, 38(12), 3280-3282 * |
| Chemical Reviews, 1977, 77, 189 * |
| Chemistry letters, 1984, 907-910 * |
| J. Carbchydr. Chem., 1990, 9, 721 * |
| Pure & Appl. Chem., 1989, 61(7), 1257-1270 * |
| Tetrahedron letters, 1980, 21, 2683-2686 * |
| Tetrahedron letters, 36(4), 505-508 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0755939A2 (en) | 1997-01-29 |
| DE59609865D1 (en) | 2002-12-19 |
| CA2176686A1 (en) | 1996-11-17 |
| JPH08333381A (en) | 1996-12-17 |
| DE19517889C2 (en) | 1998-12-03 |
| EP0755939B1 (en) | 2002-11-13 |
| ATE227731T1 (en) | 2002-11-15 |
| EP0755939A3 (en) | 1998-11-04 |
| US5696246A (en) | 1997-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH655728A5 (en) | ERYTHROMYCIN A COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE. | |
| EP0369182B1 (en) | Antitumour saccharide conjugates | |
| EP0048967B1 (en) | Process for the production of 4'-deoxydaunorubicin and 4'-deoxydoxorubicin, and 4'-epi-4'-trifluoromethyl-sulphonyloxy-n-trifluoroacetyl daunorubicin | |
| CH622529A5 (en) | Process for the preparation of anthracycline glycosides and optically active anthracyclinones | |
| DE3444051C2 (en) | New retinoids, their preparation and use | |
| DE2555479A1 (en) | PROCESS FOR THE PREPARATION OF 3 ', 4'-ALPHA-EPOXYNEAMINE AND RELATED AMINOGLYCOSIDIC ANTIBIOTICS AND THE COMPOUNDS SO PREPARED | |
| EP0755939B1 (en) | Method for the targetted synthesis of beta-glycoside bound N-acetyl glucosamine derivatives | |
| DD141836A5 (en) | PROCESS FOR THE PRODUCTION OF POLYNUCLEOTIDES WITH A SPECIFIC SEQUENCE | |
| EP0212400A2 (en) | Method for the preparation of sphingosin derivatives | |
| EP0130327B1 (en) | Moenomycin-a derivatives, their preparation and their use as antibiotics | |
| EP0946578B1 (en) | Phosphanes, their method of production and use in metal complexes | |
| DE3028339A1 (en) | NEW INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF SPECTINOMYCIN AND ITS ANALOG AND METHOD FOR THE PRODUCTION OF THE INTERIM PRODUCTS CONCERNED | |
| DE3719377C2 (en) | Anthracycline glycosides, processes for their preparation and medicaments containing them | |
| Knoben et al. | Synthesis of N-unsubstituted, mono-and disubstituted carbohydrate-1-O-carbamates and their behaviour in glycoside syntheses | |
| EP0440078B1 (en) | Process for the preparation of retinylglycosides and intermediates for this process | |
| DE3106463C2 (en) | Process for the preparation of derivatives of Kanamycin A. | |
| DE69727680T2 (en) | Stereospecific mannosylation with high yield | |
| Shing et al. | Synthesis of benzyl 2-azido-2-deoxy-4-O-β-D-glucopyranosyl-α-D-glucopyranoside and 1, 6-anhydro-2-azido-2-deoxy-4-O-β-D-glucopyranosyl-β-D-glucopyranose | |
| DE19517890C2 (en) | Process for the mild regioselective ring opening of 4,6-0-benzylidene acetals from hexopyranoses | |
| DE3913326A1 (en) | METHOD FOR PRODUCING ETOPOSIDES | |
| EP0365973B1 (en) | Process for preparing 4-0-alkyl-rhodomycins | |
| EP0394908A1 (en) | Process for producing glucosaminyl-epi-podophyllotoxin derivatives | |
| EP0997471A2 (en) | Process for the preparation of glycosides | |
| DE3837755A1 (en) | 4-DEMETHOXY-ANTHRACYCLINE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF | |
| DE3528654A1 (en) | METHOD FOR PRODUCING ALKYLATED HYDROXYL GROUP-FREE GLYCOSYL FLUORIDES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG, 6592 |
|
| 8339 | Ceased/non-payment of the annual fee |